Vir Biotechnology partnership

Graphic: Gilead cancer drug pipeline deal with Vir, showing $90 million upfront and $1.74 billion in milestones

Gilead Cancer Drug Pipeline Gets Bold Bet With Vir

Megan Wood6 hours ago58 minutes ago011 mins

The Gilead cancer drug pipeline adds three early Vir T-cell engagers. $90M upfront, up to about $1.88B in total. How the deal works and what is unknown.